NCT02821858View on ClinicalTrials.gov

Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

September 9, 2016

Study Completion Date

September 30, 2016

Conditions
Healthy
Interventions
DRUG

Odalasvir (ODV)

ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.

DRUG

AL-335

AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.

DRUG

Placebo

Matching placebo will be administered.

Trial Locations (1)

Unknown

Surrey

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02821858 - Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter